Blincyto Approved for Leukemia


The United States Food and Drug Administration (FDA) has approved Blincyto (blinatumomab) for the treatment of patients with Philadelphia chromosome-negative precurose B-cell acute lymphoblastic leukemia (B-cell ALL).

Leukemia is a type of cancer that originates in immune cells. There are several different types of leukemia, depending upon variables such as which type of immune cells affected by cancer, as well as the genetics, molecular markers, aggressiveness and characteristics of the cancer cells.

Precursor B-cell ALL is not a common type of leukemia; however, it is rapidly growing. Blincyto is referred to as a type of immune therapy, and helps harness a patient’s immune system to fight the cancer.

Blincyto is approved for patients whose leukemia has returned following therapy, or had not responded to prior therapies.

Reference: United States Food and Drug Administration (FDA). FDA approves Blincyto to treat a rare form of acute lymphoblastic leukemia. Available at: Accessed December 11, 2014.